{Reference Type}: Case Reports
{Title}: [Type 1 primary hyperoxaluria: From childhood to adult, how to manage adequately medical therapy compliance?]
{Author}: Leflot M;Krzesinski JM;Collard L;Thomas A;Ghuysen MS;
{Journal}: Nephrol Ther
{Volume}: 14
{Issue}: 3
{Year}: May 2018
{Factor}: 0.5
{DOI}: 10.1016/j.nephro.2017.06.004
{Abstract}: We report the cases of three young patients suffering from type 1 primary hyperoxaluria, a metabolic genetic disorder characterized by intracellular accumulation of oxalate and which may result in end-stage renal disease with systemic impairment. A number of effective conservative therapeutic means are available for early management of affected children particularly when he is growing older. Despite the demonstrated efficacy of conservative therapy, compliance represents a major and daily challenge. Monitoring therapeutic compliance is thus an important task for physicians in charge of this disease. A better understanding of non-compliance causes is required to improve the follow-up of patients for whom treatment education must be a priority.